{"pmid":32370991,"title":"COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.","text":["COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.","Gynecol Oncol","Monk, Bradley J","Coleman, Robert L","Moore, Kathleen N","Herzog, Thomas J","Secord, Angeles Alvarez","Matulonis, Ursula A","Slomovitz, Brian M","Guntupalli, Saketh R","O'Malley, David M","32370991"],"journal":"Gynecol Oncol","authors":["Monk, Bradley J","Coleman, Robert L","Moore, Kathleen N","Herzog, Thomas J","Secord, Angeles Alvarez","Matulonis, Ursula A","Slomovitz, Brian M","Guntupalli, Saketh R","O'Malley, David M"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32370991","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ygyno.2020.04.703","keywords":["covid-19","oral","ovarian cancer","sars-cov-2","targeted therapy"],"locations":["ovarian"],"topics":["Prevention"],"weight":1,"_version_":1666138496437321728,"score":9.490897,"similar":[{"pmid":32275775,"title":"Management of ovarian cancer during the COVID-19 pandemic.","text":["Management of ovarian cancer during the COVID-19 pandemic.","Int J Gynaecol Obstet","Mandato, Vincenzo Dario","Aguzzoli, Lorenzo","32275775"],"journal":"Int J Gynaecol Obstet","authors":["Mandato, Vincenzo Dario","Aguzzoli, Lorenzo"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275775","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/ijgo.13167","keywords":["covid-19","neoadjuvant chemotherapy","ovarian cancer","upfront surgery"],"locations":["ovarian"],"topics":["Prevention"],"weight":1,"_version_":1666138491698806784,"score":111.05569},{"pmid":32476155,"title":"Management of patients with ovarian cancer in the COVID-19 era.","text":["Management of patients with ovarian cancer in the COVID-19 era.","At the beginning of 2020, coronavirus disease 2019 (COVID-19) spreads worldwide. Patients with ovarian cancer should be considered at high-risk of developing severe morbidity related to COVID-19. Most of them are diagnosed in advanced stages of disease, and they are fragile. Here, we evaluated the major impact of COVID-19 on patients with ovarian cancer, discussing the effect of the outbreak on medical and surgical treatment.","J Surg Oncol","Bogani, Giorgio","Casarin, Jvan","Pinelli, Ciro","Di Donato, Violante","Bosio, Sara","Ruisi, Simona","Brusadelli, Claudia","Guerrisi, Rocco","Sarpietro, Giuseppe","Ditto, Antonino","Ghezzi, Fabio","Raspagliesi, Francesco","32476155"],"abstract":["At the beginning of 2020, coronavirus disease 2019 (COVID-19) spreads worldwide. Patients with ovarian cancer should be considered at high-risk of developing severe morbidity related to COVID-19. Most of them are diagnosed in advanced stages of disease, and they are fragile. Here, we evaluated the major impact of COVID-19 on patients with ovarian cancer, discussing the effect of the outbreak on medical and surgical treatment."],"journal":"J Surg Oncol","authors":["Bogani, Giorgio","Casarin, Jvan","Pinelli, Ciro","Di Donato, Violante","Bosio, Sara","Ruisi, Simona","Brusadelli, Claudia","Guerrisi, Rocco","Sarpietro, Giuseppe","Ditto, Antonino","Ghezzi, Fabio","Raspagliesi, Francesco"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476155","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jso.26057","keywords":["covid-19","sars-cov","chemotherapy","ovarian cancer","surgery"],"locations":["ovarian","ovarian","ovarian"],"topics":["Prevention"],"weight":1,"_version_":1668437835049336832,"score":107.9977},{"pmid":32416433,"title":"Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","text":["Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department.","Lung Cancer","Rossi, David","32416433"],"abstract":["COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department."],"journal":"Lung Cancer","authors":["Rossi, David"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416433","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.lungcan.2020.05.001","keywords":["lung cancer","oral","vinorelbine"],"locations":["Italy","vinorelbine"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666994545903009792,"score":70.76498},{"pmid":32413736,"pmcid":"PMC7205724","title":"Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.","text":["Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.","The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.","Int Immunopharmacol","Saghazadeh, Amene","Rezaei, Nima","32413736"],"abstract":["The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."],"journal":"Int Immunopharmacol","authors":["Saghazadeh, Amene","Rezaei, Nima"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413736","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.intimp.2020.106560","keywords":["covid-19","corticosteroids","immunoglobulin","interleukin 6","targeted therapy","treatment"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666989866115661824,"score":68.46625},{"pmid":32221023,"title":"COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers.","text":["COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers.","Int J Gynecol Cancer","Ramirez, Pedro T","Chiva, Luis","Eriksson, Ane Gerda Z","Frumovitz, Michael","Fagotti, Anna","Gonzalez Martin, Antonio","Jhingran, Anuja","Pareja, Rene","32221023"],"journal":"Int J Gynecol Cancer","authors":["Ramirez, Pedro T","Chiva, Luis","Eriksson, Ane Gerda Z","Frumovitz, Michael","Fagotti, Anna","Gonzalez Martin, Antonio","Jhingran, Anuja","Pareja, Rene"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221023","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1136/ijgc-2020-001419","keywords":["cervical cancer","ovarian cancer","pathology","radiation","surgery"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138492263989252,"score":63.509254}]}